AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
menadione 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1683 | 58-27-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
| 2 | mg | P |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM1,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ULK2 | 75 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AURKB,AXL,BRAF,CAMK2D,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3A,MAP2K3,MAP2K6,MAP3K14,MAPK1,MAPK12,MAPK7,MARK4,MET,PIK3CB,PIK3CD,PRKDC,SIK2,STK33,TEK,TTK,ULK1 | 31 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | LILLY |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosis | 56.43 | 40.98 | 12 | 295 | 14759 | 110574233 |
| Rubber sensitivity | 48.78 | 40.98 | 8 | 299 | 2410 | 110586582 |
| Pulmonary function test decreased | 44.44 | 40.98 | 9 | 298 | 8691 | 110580301 |
| Rhonchi | 43.78 | 40.98 | 8 | 299 | 4510 | 110584482 |
| Product administered at inappropriate site | 42.37 | 40.98 | 8 | 299 | 5385 | 110583607 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B02BA02 | BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS VITAMIN K AND OTHER HEMOSTATICS Vitamin K |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:48422 | angiogenesis inhibitor |
| CHEBI has role | CHEBI:50733 | nutraceutical |
| CHEBI has role | CHEBI:84087 | human urinary metabolite |
| CHEBI has role | CHEBI:147285 | EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor |
Related Drugs by ATC class:
B02BA Vitamin K 1 drug
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Aldehyde oxidase | Enzyme | IC50 | 4 | CHEMBL | |||||
| Glutathione reductase, mitochondrial | Enzyme | Ki | 4.92 | CHEMBL | |||||
| Amine oxidase [flavin-containing] B | Enzyme | Ki | 6.40 | CHEMBL | |||||
| Amine oxidase [flavin-containing] A | Enzyme | Ki | 4.59 | CHEMBL | |||||
| Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 6 | CHEMBL | |||||
| M-phase inducer phosphatase 2 | Enzyme | IC50 | 5.66 | CHEMBL | |||||
| Dual specificity phosphatase Cdc25C | Enzyme | IC50 | 4.73 | CHEMBL | |||||
| Ubiquitin carboxyl-terminal hydrolase isozyme L3 | Enzyme | IC50 | 4.15 | CHEMBL | |||||
| Dual specificity phosphatase Cdc25A | Enzyme | IC50 | 5.16 | CHEMBL | |||||
| Alpha-synuclein | Transporter | IC50 | 4.82 | CHEMBL | |||||
| Trypanothione reductase | Enzyme | IC50 | 4.26 | CHEMBL | |||||
| Dual specificity protein phosphatase 6 | Enzyme | IC50 | 4.69 | CHEMBL | |||||
| Dual specificity protein phosphatase 1 | Enzyme | IC50 | 4.62 | CHEMBL | |||||
| Replicase polyprotein 1ab | Enzyme | IC50 | 5.43 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019127 | VUID |
| N0000147378 | NUI |
| D02335 | KEGG_DRUG |
| 1182-68-9 | SECONDARY_CAS_RN |
| 4019127 | VANDF |
| C0025270 | UMLSCUI |
| CHEBI:28869 | CHEBI |
| VK3 | PDB_CHEM_ID |
| CHEMBL590 | ChEMBL_ID |
| DB00170 | DRUGBANK_ID |
| CHEMBL4297659 | ChEMBL_ID |
| 4055 | PUBCHEM_CID |
| 723JX6CXY5 | UNII |
| DB15381 | DRUGBANK_ID |
| 42781 | RXNORM |
| 337527 | MMSL |
| 35482 | MMSL |
| NOCODE | MMSL |
| d09345 | MMSL |
| 001039 | NDDF |
| 012756 | NDDF |
| 22606007 | SNOMEDCT_US |
| 412244007 | SNOMEDCT_US |
| 69576000 | SNOMEDCT_US |
Pharmaceutical products:
None